Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.51 |
| ▸ | POLA1 | P09884 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 13/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 13/20 | 0.41 |
| ▸ | CDK2 | P24941 | 12/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 11/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 11/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | MGMT | P16455 | 2/20 | 0.38 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.36 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4534389 | 0.78 | CDK2 (0.40) | PDPK1CDK1CCNB1CDK2CCNA2 | |
| SCHEMBL30677864 | 0.76 | PDPK1 (0.58) | PDPK1POLA1CDK1CCNB1CDK2 | |
| SCHEMBL3137199 | 0.75 | DPP4 (0.56) | PDPK1POLA1CDK2CTSSCTSK | |
| SCHEMBL1233712 | 0.75 | PDPK1 (0.59) | PDPK1POLA1CDK1CCNB1CDK2 | |
| Methylguanine SCHEMBL29903462 | 0.75 | CDK1 (0.69) | PDPK1CDK1CCNB1CDK2CCNA2 | |
| SCHEMBL9503859 | 0.75 | PDPK1 (0.56) | PDPK1POLA1CDK1CCNB1CDK2 | |
| SCHEMBL1443987 | 0.75 | PDPK1 (0.56) | PDPK1POLA1CDK1CCNB1CDK2 | |
| Methylguanine SCHEMBL231097 | 0.75 | CDK1 (0.69) | PDPK1CDK1CCNB1CDK2CCNA2 | |
| SCHEMBL3136203 | 0.75 | CDK2 (0.40) | PDPK1CDK2CTSSCTSK | |
| SCHEMBL3137133 | 0.74 | XDH (0.59) | CDK1CCNB1CDK2CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325982-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN T | 2009-12-31 | — | — | US | disclosed |
| US-20080269260-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN T | 2008-10-30 | — | — | US | disclosed |
| US-7335654-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1551837-A1 | PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040102460-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. | 2004-05-27 | — | — | US | disclosed |
| WO-2004014911-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269260-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE3A | PDPK1 538/4885POLA1 1154/4885CDK1 775/4885 |
| US-20040102460-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE3A, PDE3B | PDPK1 320/4885POLA1 610/4885CDK1 772/4885 |
| US-20090325982-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE3A | PDPK1 538/4885POLA1 1154/4885CDK1 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.